Skip to content

Released Mar 20, 2025, after the close

10-K filed Mar 20, 2025, 79 days after period end · 0001390478-25-000003

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$6.74MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$6,918,000N/M
Operating Cash Flowderived-$7,153,000N/M

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue—$0.00$0.00$0.00
Net Income-$6.74M-$8.14M-$9.12M-$6.60M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR